Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer.

Hennigan ST, Trostel SY, Terrigino NT, Voznesensky OS, Schaefer RJ, Whitlock NC, Wilkinson S, Carrabba NV, Atway R, Shema S, Lake R, Sweet AR, Einstein DJ, Karzai F, Gulley JL, Chang P, Bubley GJ, Balk SP, Ye H, Sowalsky AG.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00176. Epub 2019 Sep 9.

2.

Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident.

Poluben L, Puligandla M, Neuberg D, Bryke CR, Hsu Y, Shumeiko O, Yuan X, Voznesensky O, Pihan G, Adam M, Fraenkel E, Rasnic R, Linial M, Klymenko S, Balk SP, Fraenkel PG.

Am J Hematol. 2019 Jan;94(1):62-73. doi: 10.1002/ajh.25307. Epub 2018 Oct 31.

3.

Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer.

Russo JW, Gao C, Bhasin SS, Voznesensky OS, Calagua C, Arai S, Nelson PS, Montgomery B, Mostaghel EA, Corey E, Taplin ME, Ye H, Bhasin M, Balk SP.

Cancer Res. 2018 Nov 15;78(22):6354-6362. doi: 10.1158/0008-5472.CAN-18-0687. Epub 2018 Sep 21.

4.

Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer.

Russo JW, Liu X, Ye H, Calagua C, Chen S, Voznesensky O, Condulis J, Ma F, Taplin ME, Einstein DJ, Balk SP, Chen S.

Cancer Lett. 2018 Dec 1;438:97-104. doi: 10.1016/j.canlet.2018.09.014. Epub 2018 Sep 11.

PMID:
30217568
5.

Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.

Sowalsky AG, Ye H, Bhasin M, Van Allen EM, Loda M, Lis RT, Montaser-Kouhsari L, Calagua C, Ma F, Russo JW, Schaefer RJ, Voznesensky OS, Zhang Z, Bubley GJ, Montgomery B, Mostaghel EA, Nelson PS, Taplin ME, Balk SP.

Cancer Res. 2018 Aug 15;78(16):4716-4730. doi: 10.1158/0008-5472.CAN-18-0610. Epub 2018 Jun 19.

6.

SATB1 and bladder cancer: Is there a functional link?

Choudhary D, Clement JM, Choudhary S, Voznesensky O, Pilbeam CC, Woolbright BL, Taylor JA 3rd.

Urol Oncol. 2018 Mar;36(3):93.e13-93.e21. doi: 10.1016/j.urolonc.2017.10.004. Epub 2017 Oct 25.

PMID:
29079132
7.

Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients.

DeLeonardis K, Sedgwick K, Voznesensky O, Matloff E, Hofstatter E, Balk S, Tung N.

Breast J. 2017 Jul;23(4):461-464. doi: 10.1111/tbj.12764. Epub 2017 Jan 31.

PMID:
28139868
8.

A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.

McKay RR, Werner L, Mostaghel EA, Lis R, Voznesensky O, Zhang Z, Marck BT, Matsumoto AM, Domachevsky L, Zukotynski KA, Bhasin M, Bubley GJ, Montgomery B, Kantoff PW, Balk SP, Taplin ME.

Clin Cancer Res. 2017 Feb 15;23(4):935-945. doi: 10.1158/1078-0432.CCR-16-0987. Epub 2016 Sep 28. Erratum in: Clin Cancer Res. 2017 Jul 15;23 (14 ):3970.

9.

ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.

Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel EA, Nelson PS, Taplin ME, Balk SP, Cai C.

Clin Cancer Res. 2016 Jul 15;22(14):3672-82. doi: 10.1158/1078-0432.CCR-15-2309. Epub 2016 Mar 2.

10.

Increased expression of L-selectin (CD62L) in high-grade urothelial carcinoma: A potential marker for metastatic disease.

Choudhary D, Hegde P, Voznesensky O, Choudhary S, Kopsiaftis S, Claffey KP, Pilbeam CC, Taylor JA 3rd.

Urol Oncol. 2015 Sep;33(9):387.e17-27. doi: 10.1016/j.urolonc.2014.12.009. Epub 2015 Jan 22.

11.

Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.

Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, Balk SP, Taplin ME.

Clin Cancer Res. 2015 Mar 15;21(6):1273-80. doi: 10.1158/1078-0432.CCR-14-1220. Epub 2014 Oct 15.

12.

Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer.

McKay RR, Zukotynski KA, Werner L, Voznesensky O, Wu JS, Smith SE, Jiang Z, Melnick K, Yuan X, Kantoff PW, Montgomery B, Balk SP, Taplin ME.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):325-31. doi: 10.1038/pcan.2014.28. Epub 2014 Aug 5.

13.

Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.

Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP.

Clin Cancer Res. 2014 Mar 15;20(6):1590-600. doi: 10.1158/1078-0432.CCR-13-1863. Epub 2014 Jan 21.

14.

Prostaglandin E2 acts via bone marrow macrophages to block PTH-stimulated osteoblast differentiation in vitro.

Choudhary S, Blackwell K, Voznesensky O, Deb Roy A, Pilbeam C.

Bone. 2013 Sep;56(1):31-41. doi: 10.1016/j.bone.2013.04.017. Epub 2013 Apr 29.

15.

Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice.

Xu M, Choudhary S, Voznesensky O, Gao Q, Adams D, Diaz-Doran V, Wu Q, Goltzman D, Raisz LG, Pilbeam CC.

Bone. 2010 Aug;47(2):341-52. doi: 10.1016/j.bone.2010.05.006. Epub 2010 May 13.

16.

Parathyroid hormone induction of cyclooxygenase-2 in murine osteoblasts: role of the calcium-calcineurin-NFAT pathway.

Huang H, Chikazu D, Voznesensky OS, Herschman HR, Kream BE, Drissi H, Pilbeam CC.

J Bone Miner Res. 2010 Apr;25(4):819-29. doi: 10.1359/jbmr.091019.

17.

Regulation of the prostaglandin pathway during development of invasive bladder cancer in mice.

Taylor JA 3rd, Ristau B, Bonnemaison M, Voznesensky OS, Hegde P, Kuchel GA, Pilbeam CC.

Prostaglandins Other Lipid Mediat. 2009 Jan;88(1-2):36-41. doi: 10.1016/j.prostaglandins.2008.09.003. Epub 2008 Sep 12.

18.

Null mutation for macrophage migration inhibitory factor (MIF) is associated with less aggressive bladder cancer in mice.

Taylor JA 3rd, Kuchel GA, Hegde P, Voznesensky OS, Claffey K, Tsimikas J, Leng L, Bucala R, Pilbeam C.

BMC Cancer. 2007 Jul 24;7:135.

19.

Cyclooxygenase-2 gene disruption promotes proliferation of murine calvarial osteoblasts in vitro.

Xu Z, Choudhary S, Okada Y, Voznesensky O, Alander C, Raisz L, Pilbeam C.

Bone. 2007 Jul;41(1):68-76. Epub 2007 Mar 21.

20.

Overexpression of COX-2 in human osteosarcoma cells decreases proliferation and increases apoptosis.

Xu Z, Choudhary S, Voznesensky O, Mehrotra M, Woodard M, Hansen M, Herschman H, Pilbeam C.

Cancer Res. 2006 Jul 1;66(13):6657-64.

21.

Fluid flow induces Rankl expression in primary murine calvarial osteoblasts.

Mehrotra M, Saegusa M, Wadhwa S, Voznesensky O, Peterson D, Pilbeam C.

J Cell Biochem. 2006 Aug 1;98(5):1271-83.

PMID:
16514640
22.

Role of Cbfa1/Runx2 in the fluid shear stress induction of COX-2 in osteoblasts.

Mehrotra M, Saegusa M, Voznesensky O, Pilbeam C.

Biochem Biophys Res Commun. 2006 Mar 24;341(4):1225-30. Epub 2006 Jan 30.

PMID:
16476583
23.

Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfa1 binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo. 2002.

Chikazu D, Li X, Kawaguchi H, Sakuma Y, Voznesensky OS, Adams DJ, Xu M, Hoshi K, Katavic V, Herschman HR, Raisz LG, Pilbeam CC.

J Bone Miner Res. 2005 Oct;20(10):1888-98. No abstract available.

25.

Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfal binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo.

Chikazu D, Li X, Kawaguchi H, Sakuma Y, Voznesensky OS, Adams DJ, Xu M, Hoshio K, Katavic V, Herschman HR, Raisz LG, Pilbeam CC.

J Bone Miner Res. 2002 Aug;17(8):1430-40.

26.

Identification of multiple cis-acting elements mediating the induction of prostaglandin G/H synthase-2 by phorbol ester in murine osteoblastic cells.

Okada Y, Voznesensky O, Herschman H, Harrison J, Pilbeam C.

J Cell Biochem. 2000 May;78(2):197-209.

PMID:
10842315
27.

Transforming growth factor-beta1 regulation of prostaglandin G/H synthase-2 expression in osteoblastic MC3T3-E1 cells.

Pilbeam C, Rao Y, Voznesensky O, Kawaguchi H, Alander C, Raisz L, Herschman H.

Endocrinology. 1997 Nov;138(11):4672-82.

PMID:
9348193
28.

Regulation of inducible prostaglandin G/H synthase by interleukin-1, transforming growth factors-alpha and -beta, and prostaglandins in bone cells.

Pilbeam CC, Kawaguchi H, Voznesensky OS, Alander CB, Raisz LG.

Adv Exp Med Biol. 1997;400B:617-23. No abstract available.

PMID:
9547612
29.

Interleukin-4 inhibits prostaglandin G/H synthase-2 and cytosolic phospholipase A2 induction in neonatal mouse parietal bone cultures.

Kawaguchi H, Nemoto K, Raisz LG, Harrison JR, Voznesensky OS, Alander CB, Pilbeam CC.

J Bone Miner Res. 1996 Mar;11(3):358-66.

PMID:
8852946
30.

Autoregulation of inducible prostaglandin G/H synthase in osteoblastic cells by prostaglandins.

Pilbeam CC, Raisz LG, Voznesensky O, Alander CB, Delman BN, Kawaguchi H.

J Bone Miner Res. 1995 Mar;10(3):406-14.

PMID:
7785462
31.

Regulation of the two prostaglandin G/H synthases by parathyroid hormone, interleukin-1, cortisol, and prostaglandin E2 in cultured neonatal mouse calvariae.

Kawaguchi H, Raisz LG, Voznesensky OS, Alander CB, Hakeda Y, Pilbeam CC.

Endocrinology. 1994 Sep;135(3):1157-64.

PMID:
8070358
32.

Differential regulation of inducible and constitutive prostaglandin endoperoxide synthase in osteoblastic MC3T3-E1 cells.

Pilbeam CC, Kawaguchi H, Hakeda Y, Voznesensky O, Alander CB, Raisz LG.

J Biol Chem. 1993 Dec 5;268(34):25643-9.

Supplemental Content

Loading ...
Support Center